CORT - Corcept Therapeutics Incorporated

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Show:
Income Statement
Balance Sheet
Cash Flow
Annual
Subscribe to Premium to download historical data

Income Statement

All numbers in thousands
Get access to 40+ years of historical data with Yahoo Finance Premium.Learn more
Breakdown
ttm
12/31/2019
12/31/2018
12/31/2017
12/31/2016
Total Revenue
334,904
306,486
251,247
159,201
81,321
Cost of Revenue
6,142
5,504
5,215
3,554
2,058
Gross Profit
328,762
300,982
246,032
155,647
79,263
Operating Expense
198,401
189,376
156,536
102,792
69,084
Operating Income
130,361
111,606
89,496
52,855
10,179
Net Non Operating Interest Income Expense
5,444
5,070
2,657
-49
-2,039
Pretax Income
135,805
116,676
92,153
52,806
8,140
Tax Provision
29,833
22,495
16,743
-76,316
-
Net Income Common Stockholders
105,972
94,181
75,410
129,122
8,140
Diluted NI Available to Com Stockholders
105,972
94,181
75,410
129,122
8,140
Basic EPS
-
-
0
0.0011
0
Diluted EPS
-
-
0
0.001
0
Basic Average Shares
-
-
115,343
113,527
110,566
Diluted Average Shares
-
-
126,688
124,515
116,139
Total Operating Income as Reported
130,361
111,606
89,496
52,855
10,179
Total Expenses
204,543
194,880
161,751
106,346
71,142
Net Income from Continuing & Discontinued Operation
105,972
94,181
75,410
129,122
8,140
Normalized Income
105,972
94,181
75,410
129,122
8,140
Interest Income
5,444
5,070
2,657
-49
-
Interest Expense
-
-
-
49
2,039
Net Interest Income
5,444
5,070
2,657
-49
-2,039
EBIT
130,361
111,606
89,496
52,855
10,179
EBITDA
132,625
-
-
-
-
Reconciled Cost of Revenue
6,142
5,504
5,215
3,554
2,058
Reconciled Depreciation
2,264
2,171
236
106
87
Net Income from Continuing Operation Net Minority Interest
105,972
94,181
75,410
129,122
8,140
Normalized EBITDA
132,625
113,777
89,732
52,961
10,266
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0